Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. The company has a collaboration agreement with Radius Health, Inc. to develop liquid biopsy companion diagnostic for elacestrant; and has partnership with Vall d'Hebron Institute of Oncology to establish first guardant-based liquid biopsy testing service in Europe. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.